EnSite Velocity Cardiac Mapping System, EnSite Precision Cardiac Mapping System— 510(k) K201181

Name: FDA 510(k) clearance K201181
Creator: U.S. Food and Drug Administration
Published: 2020-06-26

Substantially Equivalent

ABBOTT MEDICAL

FDA 510(k) clearance K201181 for EnSite Velocity Cardiac Mapping System, EnSite Precision Cardiac Mapping System, Substantially Equivalent on 2020-06-26. Applicant: ABBOTT MEDICAL. Device class: 2.

Clearance details

Applicant: ABBOTT MEDICAL
Product code: Code DQK
Device class: Class 2
Regulation: 21 CFR 870.1425
Advisory panel: Cardiovascular
Date received: 2020-04-30
Decision date: 2020-06-26
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Plymouth, MN, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code DQK

view all

K253692 — AVVIGO+ Multi-Modality Guidance System2026-08-21
K262005 — Affera Integrated Mapping System2026-08-21
K253576 — CorVista System® with PCWP Add-On2026-07-26
K262006 — EnSite X EP System2026-07-15
K252978 — ScioCardio ECG Analysis Platform2026-07-09

More clearances from ABBOTT MEDICAL

view all

K261631 — Amplatzer TorqVue Exchange System2026-06-17
K253459 — OPTIS Mobile Next Imaging System (1014932) +2 more2026-04-24
K260212 — EnSite X EP System2026-04-20
K253907 — Disposable Radiofrequency Cannula2026-04-16
K260499 — Amplatzer Trevisio Intravascular Delivery System +1 more2026-03-13

Adverse events under product code DQK

product code DQK

Death: 10
Injury: 225
Malfunction: 2,123
Other: 2
Total: 2,360

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.